| Name | Title | Contact Details |
|---|
CredSimple is a new kind of Credentials Verification Organization (CVO) built on sophisticated technology and a partnership mindset. Payers choose us above competitors because these core values allow us to make a meaningful difference to their operations and, therefore, business.
Kaléo is dedicated to inventing, manufacturing and commercializing life-transforming products that empower patients and families to live fuller, bolder lives. We are committed to developing solutions that support the healthcare provider-patient relationship, improving access to our products.
Orbus Therapeutics is dedicated to developing products that treat rare diseases for which there are few, if any, effective therapies. The company’s product candidate in development is eflornithine in an oral solution. Eflornithine is a novel cytostatic agent, which Orbus Therapeutics is developing for the treatment of patients with anaplastic glioma (AG), or Grade 3 glioma, a rare form of central nervous system cancer. Eflornithine irreversibly inhibits ornithine decarboxylase (ODC), a key enzyme in mammalian polyamine biosynthesis that is up-regulated in various types of cancer. Orbus Therapeutics intends to develop and commercialize eflornithine in North America.
Amino, the leading healthcare guidance platform, connects people with high-quality, cost-effective providers and benefits programs in context across the healthcare ecosystem. With more than 17B healthcare claims used to inform our actionable healthcare recommendations, Amino reduces wasteful claims spending, streamlines care routing, increases care quality, and improves member experience.
Avid Radiopharmaceuticals Inc is a Philadelphia, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.